Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,628.40
(
-0.39%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
103.97
(
-0.45%
)
Bitcoin
70,435.00
(
0.77%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 176632

Thursday, 04/10/2014 4:31:24 PM

Thursday, April 10, 2014 4:31:24 PM

Post# of 257262

French plan to push copycat biotech drugs worries Big Pharma.

Big Pharma can live with European biosimilars that are not interchangeable and have to be marketed as a distinct branded drug.

p.s. New drugs approved by the EMA are entitled to 10 years of marketing exclusivity (and an eleventh year if an second indication is approved).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now